[A clinical trial of sulindac in osteoarthrosis].
45 patients wih degenerative joint diseases (osteoarthrosis of the hip or knee, Heberden's nodes) were treated for 5 weeks in an open controlled trial with Sulindac, a new nonsteroidal antirheumatic drug (300-400 mg daily). The effectiveness of the drug was evaluated by the following criteria: changes of pain intensity with active movements, pain at rest, night pain, duration of morning stiffness and limitation of movement. Analysis of the global data showed in 64,4% excellent results. In 9.9% the results were good, in 17,8% moderate and there was no response in 6.6%. Other side effects (epigastric pain 8,9%, dizziness 2,2%) were not serious and reversible during the treatment with Sulindac.
D002986:Clinical Trials as Topic; D005260:Female; D006621:Hip Joint; D006801:Humans; D007192:Indenes / Q000627:therapeutic use*; D007592:Joint Diseases / Q000188:drug therapy; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D013467:Sulindac / Q000627:therapeutic use*
D007192:Indenes; D013467:Sulindac
Sulindac: Klinische Prüfung bei Arthrosen.